se of photoliasis and topical antioxidants in the treatment of actinic keratosis and skin cancer field: a randomized controlled trial

Faculdade de Medicina de Botucatu - UNESP0 个研究点开始时间: 2020年1月27日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Sign the Informed Consent Form; Age between 50 and 90 years of both sexes; Present at least three and at most ten lesions clinically compatible with actinic keratosis in each forearm, bilaterally.

•Fewer than three or more than ten injuries in each forearm; Selected treatment area that has atypical clinical appearance or other extensive forearm dermatoses; Current and prior clinical diagnosis or evidence of any medical condition that exposes the patient to increased risks, interferes with the safety or efficacy of the proposed treatment; Have hypersensitivity or allergy to any of the subtances under study; Patients using any systemic or topical immunosuppressive substance, oral retinoid, and other local treatments (eg corticosteroids, anti-inflammatory drugs, retinoids); Immunocompromised individuals; Coagulation disorders; Suspected or confirmed pregnancy. Note: Women of childbearing age should receive urinary Beta HCG at the beginning of treatment to exclude incipient pregnancy; Women of childbearing age who do not use contraception;
•Breastfeeding women

发起方

Faculdade de Medicina de Botucatu - UNESP